Pharma Aids Limited (DSE:PHARMAID)
Bangladesh
· Delayed Price · Currency is BDT 518.30
+2.30 (0.45%)
At close: Dec 4, 2025
Pharma Aids Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Revenue | 453.49 | 438.09 | 421.23 | 308.49 | 323.05 | 280.29 | Upgrade
|
| Revenue Growth (YoY) | 5.19% | 4.00% | 36.55% | -4.50% | 15.25% | 3.98% | Upgrade
|
| Cost of Revenue | 314.49 | 306.09 | 291.88 | 257.2 | 219.58 | 174.95 | Upgrade
|
| Gross Profit | 139 | 131.99 | 129.36 | 51.29 | 103.47 | 105.34 | Upgrade
|
| Selling, General & Admin | 46.4 | 45.49 | 44.03 | 37.32 | 45.63 | 38.17 | Upgrade
|
| Other Operating Expenses | 0.06 | 0.14 | 0.07 | 2.21 | 1.94 | 0.07 | Upgrade
|
| Operating Expenses | 49.16 | 48.58 | 44.99 | 40.63 | 49.45 | 39.02 | Upgrade
|
| Operating Income | 89.83 | 83.41 | 84.36 | 10.66 | 54.02 | 66.33 | Upgrade
|
| Interest Expense | -2.34 | -1.75 | -0.26 | -0.24 | -0.38 | -0.9 | Upgrade
|
| Interest & Investment Income | 0.24 | 0.36 | 0.62 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.04 | -0.07 | -0.16 | -0.13 | -0.09 | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | 87.7 | 81.96 | 84.56 | 10.3 | 53.54 | 65.35 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0 | 0.37 | - | - | - | - | Upgrade
|
| Pretax Income | 87.7 | 82.32 | 84.56 | 10.3 | 53.54 | 65.35 | Upgrade
|
| Income Tax Expense | 20.3 | 18.51 | 23.38 | 16.68 | 18.78 | 15.1 | Upgrade
|
| Net Income | 67.4 | 63.82 | 61.19 | -6.38 | 34.76 | 50.26 | Upgrade
|
| Net Income to Common | 67.4 | 63.82 | 61.19 | -6.38 | 34.76 | 50.26 | Upgrade
|
| Net Income Growth | 0.03% | 4.30% | - | - | -30.83% | -4.22% | Upgrade
|
| Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| EPS (Basic) | 21.60 | 20.45 | 19.61 | -2.05 | 11.14 | 16.11 | Upgrade
|
| EPS (Diluted) | 21.60 | 20.45 | 19.61 | -2.05 | 11.14 | 16.11 | Upgrade
|
| EPS Growth | 0.03% | 4.30% | - | - | -30.83% | -4.22% | Upgrade
|
| Free Cash Flow | 8.55 | -17.37 | 22.6 | 5.06 | 29.15 | 21.12 | Upgrade
|
| Free Cash Flow Per Share | 2.74 | -5.57 | 7.25 | 1.62 | 9.34 | 6.77 | Upgrade
|
| Dividend Per Share | 3.000 | 3.000 | 2.500 | 1.000 | 5.000 | 5.000 | Upgrade
|
| Dividend Growth | 20.00% | 20.00% | 150.00% | -80.00% | - | - | Upgrade
|
| Gross Margin | 30.65% | 30.13% | 30.71% | 16.63% | 32.03% | 37.58% | Upgrade
|
| Operating Margin | 19.81% | 19.04% | 20.03% | 3.46% | 16.72% | 23.66% | Upgrade
|
| Profit Margin | 14.86% | 14.57% | 14.53% | -2.07% | 10.76% | 17.93% | Upgrade
|
| Free Cash Flow Margin | 1.88% | -3.97% | 5.37% | 1.64% | 9.02% | 7.54% | Upgrade
|
| EBITDA | 96.9 | 89.91 | 91.28 | 18.29 | 61.84 | 74.58 | Upgrade
|
| EBITDA Margin | 21.37% | 20.52% | 21.67% | 5.93% | 19.14% | 26.61% | Upgrade
|
| D&A For EBITDA | 7.06 | 6.5 | 6.92 | 7.62 | 7.82 | 8.25 | Upgrade
|
| EBIT | 89.83 | 83.41 | 84.36 | 10.66 | 54.02 | 66.33 | Upgrade
|
| EBIT Margin | 19.81% | 19.04% | 20.03% | 3.46% | 16.72% | 23.66% | Upgrade
|
| Effective Tax Rate | 23.15% | 22.48% | 27.64% | 161.99% | 35.07% | 23.10% | Upgrade
|
| Advertising Expenses | - | 0.61 | 0.75 | 0.89 | 0.97 | 0.96 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.